LLY vs SYK: fair value comparison
Eli Lilly and Company and Stryker Corporation · Updated 2026-09-12
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, LLY currently sits closer to the top of our discount ranking. SYK carries the stronger quality grade.
| LLY | SYK | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $1,115.70 | $275.56 |
| 12-month range | $862.86–$1,160.00 | $294.73–$387.02 |
| Sector rank | #14 of 113 Healthcare | #18 of 113 Healthcare |
| Quality grade | B | A |
| Leverage | High | Moderate |
| Margin trend | Expanding | Expanding |
| Revenue growth | High | Strong |
| RSI zone | Neutral | Oversold |
| DCF cross-check | Overvalued | Overvalued |
| 52-week position | The top quarter | The bottom quarter |
Full single-stock breakdowns: LLY fair value analysis · SYK fair value analysis